Arvinas Q2 2024: $1.2B cash, $150M Novartis upfront, VERITAC-2 data 4Q24/1Q25

ARVINAS, INC.

2024-Q2 EPS reported -$1.46 revenue$101,800,000

Cash, equivalents, and marketable securities $1.234B as of June 30, 2024; sufficient into 2027.
Revenue $76.5M (+$22M YoY) driven by $45.4M from Novartis ARV-766 license/asset purchase.
R&D expenses $93.7M (-$9.7M YoY); G&A $31.3M (+$5.6M) on higher personnel and professional fees.
VERITAC-2 enrollment on track to complete 4Q24; topline data now expected 4Q24/1Q25.
Novartis deal closed with $150M upfront; potential $1.01B in milestones plus royalties; leadership strengthened (CFO, President R&D, CSO, CBO).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.